C Piketty

Summary

Country: France

Publications

  1. ncbi request reprint Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease
    C Piketty
    Unité d Immunologie Clinique and Université Pierre et Marie Curie, Hopital Europeen Georges Pompidou, Paris, France
    Clin Endocrinol (Oxf) 55:325-30. 2001
  2. doi request reprint Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy
    C Charpentier
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Laboratoire de Virologie, 20 rue Leblanc, 75015 Paris, France
    Eur J Clin Microbiol Infect Dis 31:129-33. 2012
  3. ncbi request reprint Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen
    C Piketty
    Department of Immunology, INSERM U430 and Universite Pierre et Marie Curie, Paris, France
    J Infect Dis 183:1328-35. 2001
  4. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
  5. doi request reprint Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy
    C Charpentier
    Laboratoire de Virologie, AP HP, Hopital Europeen Georges Pompidou, Paris, France
    HIV Med 9:765-70. 2008
  6. doi request reprint Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia
    D Laureillard
    APHP, Department of Immunology, Georges Pompidou European Hospital, Paris, France
    HIV Med 9:514-8. 2008
  7. ncbi request reprint Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users
    C Piketty
    Unite d immunologie, Hopital Broussais, Universite Pierre et Marie Curie, Paris, France
    AIDS Care 11:429-36. 1999
  8. doi request reprint A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Paris, France
    J Med Virol 82:1819-28. 2010
  9. ncbi request reprint Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
    A Landau
    Department of Hepatology and Gastroenterology, , Paris, France
    AIDS 15:2149-55. 2001
  10. ncbi request reprint Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz
    C Piketty
    Service d immunologie clinique, Hôpital Européen Georges Pompidou and Université Pierre et Marie Curie, Paris, France
    HIV Med 3:287-9. 2002

Detail Information

Publications25

  1. ncbi request reprint Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease
    C Piketty
    Unité d Immunologie Clinique and Université Pierre et Marie Curie, Hopital Europeen Georges Pompidou, Paris, France
    Clin Endocrinol (Oxf) 55:325-30. 2001
    ..Here, we report on the efficacy and safety of the oral administration of DHEA as replacement therapy, in patients with advanced HIV disease, in a trial that was primarily aimed at assessing quality of life...
  2. doi request reprint Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy
    C Charpentier
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Laboratoire de Virologie, 20 rue Leblanc, 75015 Paris, France
    Eur J Clin Microbiol Infect Dis 31:129-33. 2012
    ..The potent action of RAL-containing treatment observed in the CD4 T cells compartment may suggest a pronounced reduced inhibition in the pool of regenerating CD4 T cells on a RAL-based therapy...
  3. ncbi request reprint Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen
    C Piketty
    Department of Immunology, INSERM U430 and Universite Pierre et Marie Curie, Paris, France
    J Infect Dis 183:1328-35. 2001
    ..The results support the relevance of the CD4 cell marker over plasma HIV load for predicting clinical outcome in patients who do not achieve full immunologic and virologic responses...
  4. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  5. doi request reprint Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy
    C Charpentier
    Laboratoire de Virologie, AP HP, Hopital Europeen Georges Pompidou, Paris, France
    HIV Med 9:765-70. 2008
    ..Here, we describe the development of RAL resistance, in both plasmatic and cellular compartments, in three heavily pretreated HIV-infected patients failing RAL-containing regimens...
  6. doi request reprint Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia
    D Laureillard
    APHP, Department of Immunology, Georges Pompidou European Hospital, Paris, France
    HIV Med 9:514-8. 2008
    ..A switch to nevirapine is regularly carried out because of the cost and side effects of efavirenz. Pharmacokinetic studies suggested that nevirapine should be initiated at full dose when used as a substitute for efavirenz...
  7. ncbi request reprint Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users
    C Piketty
    Unite d immunologie, Hopital Broussais, Universite Pierre et Marie Curie, Paris, France
    AIDS Care 11:429-36. 1999
    ..2 (1.5-18.1) (p = 0.004). Lack of legal income is a strong risk factor for progression of HIV disease in IDUs, that is independent of CD4 cell count and p24 antigenemia...
  8. doi request reprint A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Paris, France
    J Med Virol 82:1819-28. 2010
    ..A high PBMC HIV DNA level at TI was a strong predictor for more rapid treatment resumption...
  9. ncbi request reprint Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
    A Landau
    Department of Hepatology and Gastroenterology, , Paris, France
    AIDS 15:2149-55. 2001
    ..03 and 14.3 +/- 28.7 versus 22.5 +/- 23, P = 0.05, respectively). CONCLUSION: Our results indicate that combination therapy with IFN and RBV is effective in approximately 20% of co-infected patients with severe liver disease...
  10. ncbi request reprint Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz
    C Piketty
    Service d immunologie clinique, Hôpital Européen Georges Pompidou and Université Pierre et Marie Curie, Paris, France
    HIV Med 3:287-9. 2002
  11. ncbi request reprint Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis
    C Piketty
    Department of Immunologie Clinique INSERM U 430, Hopital Broussais, Paris, France
    Clin Microbiol Infect 6:117-20. 2000
    ..To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir therapy are associated with recurrence of CMV retinitis...
  12. ncbi request reprint Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial
    J Ghosn
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 8:142-7. 2007
    ..88 log(10) HIV-1 RNA copies/mL. The magnitude of the reduction in viral load suggested that lower doses might still be effective while offering adequate safety during long-term use...
  13. ncbi request reprint Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial
    O Launay
    Service de Medecine Interne, Hopital Cochin Port Royal Saint Vincent de Paul, AP HP, Paris, France
    Clin Infect Dis 38:e66-72. 2004
    ..83; 95% CI, 1.4-10.46; P=.008) was associated with an increased risk of rash. Cetirizine has no preventive effect on nevirapine-associated rash...
  14. doi request reprint HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  15. doi request reprint Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
    AIDS 23:2289-300. 2009
    ....
  16. doi request reprint Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Acquir Immune Defic Syndr 49:272-5. 2008
    ..The immunogenicity of vaccines, including vaccine against hepatitis A virus (HAV), is impaired in patients with HIV infection, requiring revised immunization regimens...
  17. ncbi request reprint Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS
    J Rambeloarisoa
    Service d immunologie clinique, Hopital Europeen Georges Pompidou, Paris, France
    J Infect 44:185-8. 2002
    ..Finally, this case raises the question of when to stop secondary prophylaxis of cryptococcal disease after increase in CD4 cell count under antiretroviral therapy...
  18. ncbi request reprint Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy
    L Weiss
    Service d immunologie clinique, Université Pierre et Marie Curie and Institut National de la Santé et de la Recherche Médicale INSERM U430, Hopital Europeen Georges Pompidou, Paris, France
    HIV Med 3:12-20. 2002
    ..To investigate the extent of functional T cell recovery and to characterize plasma virus and virus producing cells in patients with increasing CD4 cell counts despite virological failure during protease inhibitor (PI) based therapy...
  19. pmc Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era
    Caroline Charlier
    Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA 3012, Institut Pasteur, Paris, France
    PLoS ONE 3:e1950. 2008
    ..Given this, we suggest that investigation for cryptococcosis-related lesions is merited, even in the absence of neurological abnormality, if a high fungal burden is suspected on the basis of high serum and/or CSF antigen titers...
  20. ncbi request reprint Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008
    ..Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy...
  21. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  22. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  23. ncbi request reprint [Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases amd review of the literature]
    P Le Houssine
    Service d'Immunologie Clinique, , 20, rue Leblanc, 75908 Paris, France
    Rev Med Interne 22:1196-203. 2001
    ..While the life expectancy of HIV-infected patients extends, primary pulmonary hypertension occurrence could increase and call for early diagnosis, thus allowing for specific care...
  24. ncbi request reprint [Castleman's disease in patients infected with HIV]
    L Aaron
    Service de Maladies Infectieuses et Tropicales, Hopital Necker Enfants Malades, 149, rue de Sevres, 75743 Paris, France
    Rev Med Interne 23:155-63. 2002
    ..However, antiviral therapy against HHV8 or HIV and the immunitary restoration do not have any influence on the evolution of Castleman's disease, contrary to opportunistic infections...
  25. ncbi request reprint Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues
    D Batisse
    AIDS 16:2370-1. 2002